Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Seelos Therapeutics, Inc. (SEELQ : OTC)
 
 • Company Description   
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.

Number of Employees: 16

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.00 Daily Weekly Monthly
20 Day Moving Average: 1,604 shares
Shares Outstanding: 0.37 (millions)
Market Capitalization: $0.00 (millions)
Beta: 1.45
52 Week High: $4.57
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.00% -3.74%
12 Week 0.00% -15.89%
Year To Date -99.79% -99.80%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
300 PARK AVENUE 2ND FLOOR
-
NEW YORK,NY 10022
USA		 ph: 646-293-2100
fax: 858-436-8155		 anthony.marciano@seelostx.com http://www.seelostherapeutics.com
 
 • General Corporate Information   
Officers
Raj Mehra - Chief Executive Officer;President
Michael Golembiewski - Chief Financial Officer
Margaret Dalesandro - Director
Brian Lian - Director
Daniel J. O'Connor - Director

Peer Information
Seelos Therapeutics, Inc. (CORR.)
Seelos Therapeutics, Inc. (RSPI)
Seelos Therapeutics, Inc. (CGXP)
Seelos Therapeutics, Inc. (BGEN)
Seelos Therapeutics, Inc. (GTBP)
Seelos Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 81577F406
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/24
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 0.37
Most Recent Split Date: 9.00 (0.06:1)
Beta: 1.45
Market Capitalization: $0.00 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 0.00
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 107.50%
Sales Growth
vs. Year Ago Period: 11.90%
vs. Previous Quarter: -35.06%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - -
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©